Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
Celia Jonsson-OldenbüttelJade GhosnMarc van der ValkEric FlorenceFrancisco VeraStéphane De WitAgathe RamiFabrice BonnetLaurent HocquelouxKai HoveMounir Ait-KhaledRebecca DeMoorGilda BontempoChristine L LathamCassidy A GutnerSupriya IyerMartin GillMaggie CzarnogorskiRonald D'AmicoJean van WykPublished in: Journal of acquired immune deficiency syndromes (1999) (2024)
CAB + RPV LA Q2M was well tolerated and highly effective in maintaining virologic suppression with a low rate of virologic failure.